AYTU BioPharma
AYTU
37 hedge funds and large institutions have $5.39M invested in AYTU BioPharma in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 15 reducing their positions, and 7 closing their positions.
921% more call options, than puts
Call options by funds: $245K | Put options by funds: $24K
0.09% less ownership
Funds ownership: 0.77% → 0.68% (-0.09%)
5% less funds holding
Funds holding: 39 → 37 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
40% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 15
56% less capital invested
Capital invested by funds: $12.2M → $5.39M (-$6.83M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$112K |
| 2 |
BlackRock
New York
|
+$108K |
| 3 |
PSC
Piper Sandler & Co
Minneapolis,
Minnesota
|
+$107K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$59.6K |
| 5 |
Two Sigma Advisers
New York
|
+$37.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$406K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$269K |
| 3 |
D.E. Shaw & Co
New York
|
-$181K |
| 4 |
WG
Winton Group
London,
United Kingdom
|
-$165K |
| 5 |
Millennium Management
New York
|
-$139K |
AYTU Hedge Fund Activity: Q4 2021 in Review
37 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q4 2021, worth a combined $5.39M — down 56% from $12.2M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of AYTU and 5 opened new positions — a net loss of 2 holders — while 15 trimmed existing stakes and 9 added.
The largest buyer was Marshall Wace, opening a new position worth an estimated $112K. The largest seller was Morgan Stanley, cutting an estimated $406K.
- 37 institutional investors held AYTU BioPharma (AYTU) as of Q4 2021, down from 39 in Q3 2021.
- Funds reported $5.39M of AYTU BioPharma stock for Q4 2021, down 56% quarter-over-quarter.
- 5 funds opened new AYTU BioPharma positions in Q4 2021 and 7 closed out, a net change of -2 holders.
- The largest AYTU BioPharma buyer in Q4 2021 was Marshall Wace, an estimated $112K added.
- The largest AYTU BioPharma seller in Q4 2021 was Morgan Stanley, an estimated $406K sold.
Based on aggregated 13F filings for Q4 2021.